A MULTI-PART, PHASE 1, MULTI-CENTER, OPEN-LABEL, PLUS EXPANSION CLINICAL TRIAL OF AN OFF-THE-SHELF NEO-ANTIGEN HEAT SHOCK PROTEIN VACCINE (RHSC-DIPGVAX) IN COMBINATION WITH CHECKPOINT BLOCKADE FOR TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA...

Registry ID

LCH 20C05

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO

Last update

2024-04-05

Conditions

• DIFFUSE INTRINSIC PONTINE GLIOMAS

Related clinical trials

• A PILOT STUDY OF SAFETY, TOLERABILITY, AND IMMUNOLOGICAL EFFECTS OF SURVAXM IN PEDIATRIC PATIENTS WITH PROGRESSIVE OR RELAPSED MEDULLOBLASTOMA, HIGH GRADE GLIOMA, EPENDYMOMA AND NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA

View on source registry